S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Viatris Inc. Common Stock

VTRS XNAS
$17.17 -0.36 (-2.08%) ▼ 15-min delayed
Open
$17.30
High
$17.53
Low
$16.65
Volume
20.24M
Market Cap
$20.00B

About Viatris Inc. Common Stock

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 30.0K Website →

Key Financials

Period Revenue Net Income EPS
TTM 2025 $14.30B $-3,514,900,000 $-3.00
FY 2025 $14.30B $-3,514,900,000 $-3.00
Q3 2025 $3.76B $-128,200,000 $-0.11
Q2 2025 $3.58B $-4,600,000 $0.00

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026
Calendar →

Related Market News

No specific coverage for VTRS yet. Check out our latest market news or earnings calendar.

Get VTRS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Viatris Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.